Rivastigmine for Intensive Care Unit (ICU) Delirium

• Status: Terminated
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Delirium in Intensive Care (IC) patients is a frequent disorder. The aim of this study is to investigate whether treatment of delirium in the ICU with rivastigmine added to haloperidol shortens the duration of delirium in comparison to placebo added to the treatment with haloperidol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht
• Collaborators: Hersenstichting; Netherlands Brain Foundation; Novartis; ZonMw: The Netherlands Organisation for Health Research and Development
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• 18 years or older

• Positive CAM-ICU

Exclusion Criteria:

• Known allergy to rivastigmine

• Unable to receive enteric medication

• Pregnant or lactating

• Renal replacement therapy

• Hepatic encephalopathy

• Second or third degree atrioventricular block

• Uncertainty about diagnosis delirium and no confirmation by neurologist, psychiatrist or geriatrician

• Parkinson's disease.

• Lewy body dementia.

• ECG QT interval above 500 msec.

• No informed consent